MiRus Lands $1.5 B Boston Scientific Backing as Hark and Modal Secure Major AI Funding

MiRus raised a $1.5 billion round led by Boston Scientific, while AI startup Hark closed a $700 million Series A and Modal Labs reported ARR growth to $300 million.

The funding surge reflects continued investor confidence in both medical‑device innovation and AI infrastructure. Boston Scientific (BSX), with a market cap of roughly $80 billion, traded up 1.2 % yesterday, underscoring its appetite for strategic orthopedic ventures. MiRus, based in Marietta, Georgia, develops implants and treatment systems for musculoskeletal disorders and now holds $1.6 billion in total capital after the deal, which grants Boston Scientific a 34 % equity stake.

Hark, a one‑year‑old AI firm in San Jose, California, secured a $700 million Series A led by Parkway Venture Capital. The round drew participation from chip makers Nvidia (NVDA), Intel (INTC), AMD, and Qualcomm (QCOM), as well as ARK Investment Management (ARKK) and Salesforce Ventures (CRM). NVDA rose 2.5 % on the day, INTC slipped 0.8 %, AMD gained 1.8 %, QCOM was flat, ARKK added 3 %, and CRM edged up 0.5 %. Hark says it is building personalized AI devices and plans a product launch later this summer.

Modal Labs, a New York‑based provider of serverless GPU cloud tools for AI workloads, announced that its annual recurring revenue (ARR) climbed to $300 million from $60 million in September, per CEO Erik Bernhardsson. The metric signals rapid enterprise adoption of AI coding platforms as companies seek scalable compute for model training and inference.

These deals illustrate how established corporates and venture backers are allocating capital to high‑growth niches: MiRus for next‑generation spinal tech, Hark for edge‑AI hardware, and Modal for AI‑focused cloud infrastructure.

Watch for MiRus’ upcoming spinal implant trials and Hark’s hardware prototype launch later this summer.